Free tool
FAERS Monitor: Omvoh
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761279 or its brand name (Omvoh, Mirikizumab-Mrkz). Reports on generic versions are filed under their own applications.
Reports
903
Serious
489
54% of reports
Hospitalization
176
Death reported
26
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- colitis ulcerative155
- injection site pain89
- drug ineffective81
- diarrhoea37
- haematochezia35
- arthralgia30
- incorrect dose administered29
- headache27
- rash27
- frequent bowel movements25
- off label use24
- maternal exposure during pregnancy23
- abdominal pain22
- pyrexia19
- dizziness17
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2023 | 22 |
| 2024 | 312 |
| 2025 | 318 |
| 2026 | 251 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,256 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| colitis ulcerativeSignal | 155 | 81.0 | 70.2 | 12,158 |
| frequent bowel movementsSignal | 25 | 21.6 | 14.7 | 470 |
| haematocheziaSignal | 35 | 14.8 | 10.7 | 437 |
| injection site painSignal | 89 | 6.8 | 5.5 | 437 |
| maternal exposure during pregnancySignal | 23 | 6.0 | 4.0 | 92 |
| incorrect dose administeredSignal | 29 | 3.0 | 2.1 | 36 |
| abdominal painSignal | 22 | 2.2 | 1.5 | 13 |
| arthralgia | 30 | 1.7 | 1.2 | 8 |
| rash | 27 | 1.4 | 1.0 | 3 |
| drug ineffective | 81 | 1.4 | 1.2 | 11 |
| diarrhoea | 37 | 1.3 | 1.0 | 3 |
| pyrexia | 19 | 1.3 | 0.8 | 1 |
| headache | 27 | 1.0 | 0.7 | 0 |
| dizziness | 17 | 0.8 | 0.5 | 1 |
| off label use | 24 | 0.6 | 0.4 | 5 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.